To determine the frequency of mutations responsible for Gaucher's disease, we systematically sequenced the GBA1 gene as part of a molecular characterization of 73 adult patients in the United Kingdom. Five hitherto unknown pathogenic variants were identified, one of which is a splice site change; the others are novel missense mutations. Given that GBA1 gene mutations are an important risk factor for the development of Parkinson's disease, we contend that a complete analysis and molecular characterization of both the known and novel GBA1 variants will be needed before the biochemical processes underlying this genetic association can be fully understood.
Introduction
The identification of the glucocerebrosidase locus (GBA1) as a strong genetic determinant of Parkinson's disease (PD) [1] , renders it difficult to counsel patients with Gaucher's disease (GD) and their relatives as to their lifetime risk of this disorder. Furthermore, as more patients with PD are undergoing genetic analysis, GBA1 mutations of unknown significance are increasingly being found in this population. Impaired activity, function or altered processing of glucocerebrosidase causes GD [2] but the relationship of individual mutant GBA1 alleles and their effects on the structure and activity of the cognate β-glucocerebrosidase to the development of parkinsonism has yet to be determined. As part of a nationwide study of the pathogenesis of parkinsonian manifestations in adult GD patients, we have undertaken a systematic approach to the molecular characterization of the GBA1 gene as a contribution to extend the list of GD causing alleles and a previous step towards the better understanding of the functional consequences of the mutant protein which would underlie this association.
Materials and methods

Patients
Seventy-three consecutive unrelated adult patients with Type I GD were recruited from specialised clinics for patients with lysosomal diseases at the Royal Free Hospital, London, and Addenbrooke's Hospital, Cambridge. Thirty-nine (53%) were male, mean age was 50 (range 18-89 years), 16 were Ashkenazim (22%) and 4 had Eastern European ancestry (5.7%); the remainder were white UK citizens without known Ashkenazim ancestry. Genomic DNA was extracted from lymphocytes or saliva. Exons 1-11 of the GBA1 gene were sequenced using a published protocol [3] . The sequence reference and exon numbering were those of GenBank accession number NM_000157.3. Written informed consent was taken from each participant; this study was approved by the North West London and Cambridge University Hospitals ethics committees.
Results
Mutations in GBA1 in Type I ('non-neuronopathic') GD patients
One hundred and forty four mutant GBA1 alleles were identified in the patients, of these 139 had been described. In two patients only a single mutant allele was found. Fifty percent were N370S (n=74), 12% were L444P (n=19), 6.0% were RecNcil (n=8), 2.7% were R463C (n=4), 2% D409H (n=3) and 1.3% were 84GG, R120W, M123T, S173X, G202R, W184R or R496H (two for each). The following known disease-associated mutations were found as a single copy in GD patients: IVS2+1G> A, 155-156insACAGCT, 203insC, 329-333delCAGAA, L66P, R120Q, P182T, F216Y, H255Q, P266R, A318D, R359X, D380N, D380A, 1263-1317del55, L480P. In two patients a second mutation could not be identified, leaving genotype assignments as: R496H/not found and N370S/not found, in patients with a clear enzymatic deficiency and a clinical diagnosis fully consistent with Molecular Genetics and Metabolism 106 (2012) [495] [496] [497] 'non-neuronopathic' GD. When genotype does not correspond with clinical phenotype, DNA rearrangements such as deletions, fusions and/or duplications have to be considered as a consequence of recombination events. Appropriate methods are being optimized in our laboratory to investigate these possibilities.
Five novel GBA1 mutations identified in U.K Type I GD patients
We identified 5 mutations in the GBA1 gene that were hitherto unknown since they have not been reported in 2500 chromosomes sequenced by 1000 Genomes Project (http://www.1000genomes.org/): G250V (c.866G >T) (found trans to N370S), R262G (c.901C>G) (found trans to RecNil), A341V (c.1139G >A) (found trans to N370S ), IVS9+ 1G >A (c.1388+1G> A) (found trans to N370S in two patients) and V447E (c.1457T >A) (found trans to N370S). The clinical features of the subjects harbouring these mutations are summarised in Table 1 . Their GBA1 enzymatic activity values were b15% of control values consistent with a diagnosis of GD. No cognitive impairment or parkinsonian symptoms were reported. Splenic enlargement, with or without hepatomegaly was presented in four cases, whereas bone disease and thrombocytopenia occurred in two. Moreover one case presented with pancytopenia, paraproteinemia and possible myoclonic epilepsy. The severity score index [4] ranged from 4 to 10.
In silico analysis of effects of novel GBA1 mutations
While the splice site mutation would clearly indicate loss of function allele, the four missense mutations raise further questions as to their structural effects on glucocerebrosidase function. The effects of the missense mutations have been mapped onto the 3D structure of the GBA1 protein in Fig. 1 of Supplementary data by the viewer Protein Workshop [5] . We have since analyzed their effects on protein stability and malfunction by the Site Directed Mutator (SDM) bioinformatics tool [6] and the HOPE web server [7] .
Although A341V was predicted to be stabilizing, the mutant residue in the protein core was larger and could disrupt the local structure surrounding the active site. This residue together with the Asp127, Glu235, Glu340 and Asp380 residues has been located in the GBA1-substrate interaction region and participates in the correct catalytic processing of the substrate [8] . Another mutation located in the same amino acid position, A341T, was previously reported in a Type III GD patient of Finnish origin, with L444P as second allele [9] and in a Type I GD patient of Swedish ancestry, combined with N370S [10] . Both R262G and V447E were predicted to be highly destabilizing and cause protein malfunction. The loss of positive charge in R262G is likely to affect the interactions of the protein with other molecules. Another amino acid change in the same position, R262H, has been linked to PD by the Leiden Open Variant Database [11] and has been found in multiple system atrophy [3] but was not previously found in GD. Related to V447E the mutant amino acid was predicted to alter the β-sheet secondary structure found in that region. Also its negative charge is likely to cause loss of hydrophobic interactions with other molecules. In this sense, the residue has been located in the Saposin C interaction surface and contacts Ala446, involved in the proper structural arrangement of the surrounding area [8] . It is likely that the loss of hydrophobic environment damages the binding site for the Saposin C. These results were also supported by the predictions of the tools SIFT [12] and PolyPhen [13] , which indicated that all four newly identified missense mutations are likely to be pathogenic (Table 2 , Supplementary data).
Discussion
Here we report a comprehensive genotypic analysis of the GBA1 mutation spectrum in 73 Type I GD patients using Sanger sequencing technology. As predicted from numerous studies, N370S was the most common mutation; it accounted for nearly 50% of the mutant GBA1 alleles, and much greater than that reported (29%) in a smaller study reported by Hatton et al. [14] in 46 British and Irish patients with GD. This might be explained by the fact that just 22% of patients in our study were Ashkenazim. Ethnic origin has a large effect on the distribution of mutations, being particularly evident for N370S, which is not generally prevalent in the Chinese population [15] . The Turkish population has an N370S allele frequency over 30% [16] and the frequency in Iberian populations are 50.2 (Spanish) and 53.7%, (Portuguese), respectively [17, 18] almost identical to our cohort.
The number of mutations in GBA1 reported in GD is now about 220 with about 20 variants reported as non-pathogenic variants [19, 20] . Both variant types occur throughout the molecule. It is not clear whether each of the reported pathogenic variants is complete loss of function alleles and this is likely to influence the degree to which they increase the risk of PD or if other distinct effects on lysosomal machinery are also contributing. The alleles we report here clearly reduce enzymatic activity sufficiently to induce enzyme deficiency since they cause GD in combination with a second GBA1 mutant allele. Although further functional analysis of these mutations will be needed to elucidate completely the biochemical processes underlying the disease, they might substantially increase the risk of developing parkinsonism. In a previous phenotyping study, we identified an individual carrying the G250V mutation in heterozygosity and who had clinical features of early PD [21] . We report here four new missense mutations and one splice site mutation which are clearly loss of function alleles and which may, therefore, be suspected of harbouring a predisposition to PD.
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